US pharma major AbbVie’s (NYSE: ABBV) shares were up 1.5% at $147.50 pre-market, as it announced financial results for the second quarter ended June 30, 2022.
It delivered second-quarter net revenues of $14.583 billion, an increase of 4.5% on a reported basis and 6.1% operationally. This was in line with consensus estimates. Net earnings attributable to AbbVie came in at $924 million, up 20.6% compared with $766 million a year earlier
Diluted earnings per share (EPS) in the second quarter was $0.51 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.37. These results include an unfavorable impact of $0.14 per share related to acquired IPR&D and milestones expense.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze